BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond) 2022;136:197-222. [PMID: 35119068 DOI: 10.1042/CS20201474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Cunningham R, Jia S, Purohit K, Salem O, Hui NS, Lin Y, Carragher NO, Hansen CG. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations. Clin Transl Med 2023;13:e1190. [PMID: 36740402 DOI: 10.1002/ctm2.1190] [Reference Citation Analysis]
2 Pobbati AV, Kumar R, Rubin BP, Hong W. Therapeutic targeting of TEAD transcription factors in cancer. Trends Biochem Sci 2023:S0968-0004(22)00333-4. [PMID: 36709077 DOI: 10.1016/j.tibs.2022.12.005] [Reference Citation Analysis]
3 Li R, Huang W. Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Cardiovascular Diseases. Int J Mol Sci 2023;24. [PMID: 36675179 DOI: 10.3390/ijms24021666] [Reference Citation Analysis]
4 Déglise S, Bechelli C, Allagnat F. Vascular smooth muscle cells in intimal hyperplasia, an update. Front Physiol 2022;13:1081881. [PMID: 36685215 DOI: 10.3389/fphys.2022.1081881] [Reference Citation Analysis]
5 Gattupalli M, Dey P, Poovizhi S, Patel RB, Mishra D, Banerjee S. The Prospects of RNAs and Common Significant Pathways in Cancer Therapy and Regenerative Medicine. Regenerative Medicine 2023. [DOI: 10.1007/978-981-19-6008-6_16] [Reference Citation Analysis]
6 Wolska BM, Langa P, Solaro RJ. The Hippo Signaling Pathway as a Drug Target in Familial Dilated Cardiomyopathy. IJDDP 2022. [DOI: 10.53941/ijddp.v1i1.189] [Reference Citation Analysis]
7 Yang L, Wang Z, Geng R, Deng H, Niu S, Zuo H, Weng S, He J, Xu X. White Spot Syndrome Virus (WSSV) Inhibits Hippo Signaling and Activates Yki To Promote Its Infection in Penaeus vannamei. Microbiol Spectr 2022. [DOI: 10.1128/spectrum.02363-22] [Reference Citation Analysis]
8 Luo M, Xu Y, Chen H, Wu Y, Pang A, Hu J, Dong X, Che J, Yang H. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers. European Journal of Medicinal Chemistry 2022;244:114847. [DOI: 10.1016/j.ejmech.2022.114847] [Reference Citation Analysis]
9 Sun Y, Jin D, Zhang Z, Jin D, Xue J, Duan L, Zhang Y, Kang X, Lian F. The critical role of the Hippo signaling pathway in kidney diseases. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.988175] [Reference Citation Analysis]
10 Hlaváč V, Holý P, Václavíková R, Rob L, Hruda M, Mrhalová M, Černaj P, Bouda J, Souček P. Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy. Life Sci Alliance 2022;5:e202201551. [PMID: 36229065 DOI: 10.26508/lsa.202201551] [Reference Citation Analysis]
11 Fu H, Wang Q, Li H, Gao J, Liu L, Tang B, Wei D, Xu B, Tong X, Li J, Luo Y. Partition defective 3 promotes TAZ nuclear localization and promotes Amphiregulin transcription to promote liver hepatocellular carcinoma cell invasion, migration and epithelial mesenchymal.. [DOI: 10.21203/rs.3.rs-1953346/v1] [Reference Citation Analysis]
12 Mranda GM, Xiang Z, Liu J, Wei T, Ding Y. Advances in prognostic and therapeutic targets for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The hippo signaling pathway. Front Oncol 2022;12:937957. [DOI: 10.3389/fonc.2022.937957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Anwar S, Shahwan M, Hasan GM, Islam A, Hassan MI. Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy. Cell Signal 2022;99:110434. [PMID: 35961526 DOI: 10.1016/j.cellsig.2022.110434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mourkioti I, Angelopoulou A, Belogiannis K, Lagopati N, Potamianos S, Kyrodimos E, Gorgoulis V, Papaspyropoulos A. Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer. Cells 2022;11:2449. [PMID: 35954292 DOI: 10.3390/cells11152449] [Reference Citation Analysis]
15 Wu X, Xie W, Xie W, Wei W, Guo J. Beyond controlling cell size: functional analyses of S6K in tumorigenesis. Cell Death Dis 2022;13:646. [PMID: 35879299 DOI: 10.1038/s41419-022-05081-4] [Reference Citation Analysis]
16 Zhang Y, Wang Y, Ji H, Ding J, Wang K. The interplay between noncoding RNA and YAP/TAZ signaling in cancers: molecular functions and mechanisms. J Exp Clin Cancer Res 2022;41:202. [PMID: 35701841 DOI: 10.1186/s13046-022-02403-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li Y, Yang S, Yang S. Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway. Cells 2022;11:1361. [DOI: 10.3390/cells11081361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]